#151108

Anti-CD45 [HLe-1(2D1)]

Cat. #151108

Anti-CD45 [HLe-1(2D1)]

Cat. #: 151108

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Protein tyrosine phosphatase, receptor type, C (PTPRC, CD45)

Class: Monoclonal

Application: FACS ; IHC ; IF

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Peter Beverley

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CD45 [HLe-1(2D1)]
  • Alternate name: Anti-PTPRC
  • Clone: HLe-1(2D1)
  • Tool type ecom: Antibodies
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 180-220 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF
  • Description: Monoclonal antibody capable of analysing subpopulations of hematopoietic and lymphoid cells, and the degree of T cell differentiation. It can be used to identify the effect of CD45 in immune function.
  • Immunogen: Human peripheral blood mononuclear cells.
  • Immunogen uniprot id: P08575
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Protein tyrosine phosphatase, receptor type, C (PTPRC, CD45)
  • Molecular weight: 180-220 kDa
  • Target background: Anti-PTPRC (Hle-1) monoclonal antibody binds transmembrane protein tyrosine phosphatase receptor type C (PTPRC), also known as CD45 antigen or leukocyte common antigen (LCA). Anti-PTPRC can be used in a panel of several monoclonal antibodies to characterise tumours. This antibody was created to investigate the similarities between normal thymocyte subpopulations and leukaemia's of thymic origin (Thy-ALL), and aid with leukaemia diagnosis. PTPRC is present on all leukocytes. CD45 helps regulate T cell receptor-associated kinases and Janus kinases which transmit signals from cytokine receptors. This regulates the threshold of T cell antigen receptor (TCR) signalling through dephosphorylation of protein tyrosine kinases (e.g. Lck and Fyn). It is only expressed on nucleated hemopoietic cells (~10% of cell surface). CD45 phosphatase activity is required for efficient lymphocyte antigen receptor signal transduction. CD45 is a positive and negative regulator of Src family members, and can act as a JAK phosphatase, negatively regulating cytokine receptor activation (related to differentiation, proliferation and anti-viral immunity of hemopoietic cells).

Applications

  • Application: FACS ; IHC ; IF

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C

References

  • Di Liberto et al. 2016. Clin Transl Gastroenterol. 7(7):e178. PMID: 27388423.
  • Lee et al. 2004. Int Immunol. 16(8):1109-24. PMID: 15210650.
  • Tchilian et al. 2001. J Immunol. 166(2):1308-13. PMID: 11145714.
  • Bradstock et al. 1980. J Natl Cancer Inst. 65(1):33-42. PMID: 6993744.